OSE-127 (Effi-7), Interleukin-7 Antagonist (IL-7R), developed in autoimmune diseases through the consortium EFFIMab
OSE-127 (Effi-7) is a humanized monoclonal antibody targeting CD 127 receptor, the alpha chain of the Interleukin 7 receptor (IL-7R), with proof of concept confirmed in vivo in several auto-immune models.
This collaborative program, co-financed by Bpifrance, is headed by OSE Immunotherapeutics as leader of the consortium to develop OSE-127 (Effi-7), a monoclonal immunomodulatory antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R).
The product is under preclinical phase in ulcerative colitis and the funding from Bpifrance will enable to cover its development until the phase 2 clinical stage. The total amount of the OSE-127 program, being developed by OSE Immunotherapeutics in collaboration with INSERM and Nantes University Hospital, is of €20 million with €9.1 million allotted by Bpifrance.
In June 2017, the Company announced a new milestone related to the finalization of significant preclinical results for OSE-127 and translational data on the high expression of IL-7R in biopsies from patients with ulcerative colitis These data will be used to support the next clinical applications planned in inflammatory bowel diseases (results presented at the international congress of immunology of FOCIS – Federation of Clinical Immunology Societies * – Press release of June 15, 2017). In addition, the manufacturing process of OSE-127 is finalized, making it possible to advance towards pilot batch production step.
* “IL-7 pathway controls human T cell homing to the gut and culminates in inflammatory bowel disease mucosa”